Age | ||
---|---|---|
Mean ± SD, range | 30.7 ± 10.2, 48–16 | |
Sex | ||
Male | 7 | 36.84% |
Female | 12 | 63.16% |
Disease type | ||
Primary | 15 | 78.95% |
Recurrent | 3 | 15.79% |
Metastatic | 1 | 5.26% |
Location of primary lesion | ||
Pelvis/sacrum | 2 | 10.53% |
Lower extremity | 8 | 42.11% |
Upper extremity | 7 | 36.84% |
Spine | 1 | 5.26% |
Scapula | 1 | 5.26% |
Pre-denosumab treatment | ||
None | 13 | 68.42% |
Surgery | 3 | 15.79% |
Embolization | 3 | 15.79% |
Post-denosumab treatment | ||
None | 7 | 36.84% |
Surgery | 11 | 57.89% |
Embolization | 1 | 5.26% |